Dr. Huaxun Wu | Toxicology and Pharmaceutical Science | Outstanding Contribution Award
Anhui Medical University | China
Dr. Huaxun Wu is an accomplished pharmacologist and Associate Professor at Anhui Medical University, serving as a Master’s Supervisor with a strong record of academic leadership, research excellence, and translational impact in anti-inflammatory immunopharmacology and clinical pharmacology. He holds both MD and PhD degrees in Pharmacology and has established himself as a recognized contributor to pharmacological science through sustained competitive funding, high-quality publications, and active service within national and provincial academic societies. Dr. Wu has served as Principal Investigator for multiple prestigious research programs, including the National Natural Science Foundation of China (Youth Program), the Anhui Provincial Natural Science Foundation (General Program), the Anhui Provincial Key Program for Outstanding Young Talents in Universities, and the Anhui Provincial Key Program for Natural Science Research in Higher Education Institutions. These projects focus on the mechanisms of inflammation, immune regulation, and pharmacological intervention, contributing to improved understanding of drug targets and therapeutic strategies in inflammatory and immune-related diseases. With more than 30 peer-reviewed academic publications, including over 20 SCI-indexed articles, Dr. Wu’s work has achieved significant international visibility, reflected in more than 1,183 citing articles. His research demonstrates a strong balance between fundamental pharmacological discovery and methodological rigor. In addition to journal publications, he has contributed substantially to pharmacological education and research methodology through the publication of authoritative textbooks, including Pharmacological Experimental Methodology (4th Edition) and Pharmacological Research Methodology, which are widely used in academic and clinical training. Dr. Wu’s innovation capacity is further evidenced by his intellectual property portfolio, which includes one granted national patent and three granted PCT patents, underscoring the translational potential and practical relevance of his research outputs. His editorial involvement with the Chinese Pharmacology Bulletin reflects peer recognition of his expertise and commitment to maintaining high scientific standards.
1784
76
28
Citations
h-index
i10-index
View Scopus Profile
Featured Publications
CP-25 ameliorates dysfunction in the M3R-IP3R-Ca2+-AQP5 signaling pathway by inhibiting ERS in primary Sjögren’s syndrome
– International Immunopharmacology, 2026
G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren’s syndrome
– Acta Pharmacologica Sinica, 2024
Human Umbilical Cord Mesenchymal Stem Cells Alleviate Rat Knee Osteoarthritis via Activating Wnt/ β-catenin Signaling Pathway
– Current Stem Cell Research and Therapy, 2024